KM Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kmpharmaceutical makes everyday personal-care and household products, including toothpaste, toothbrushes, shampoo, body wash, skincare cosmetics, and items such as hand sanitiser, masks, and moisture-absorbing dehumidifiers.
Its products serve both infant and adult consumers across the oral-care and beauty-care markets. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core revenue comes from its oral-care and beauty-care lines, with household goods providing a supplementary but steady contribution.
Summary is AI-generated and may contain errors · figures from DART filings
KM Pharmaceutical in five facts
What does KM Pharmaceutical do?
Kmpharmaceutical makes everyday personal-care and household products, including toothpaste, toothbrushes, shampoo, body wash, skincare cosmetics, and items such as hand sanitiser, masks, and moisture-absorbing dehumidifiers.
Where is KM Pharmaceutical listed and in which sector?
KM Pharmaceutical (Korean name: 케이엠제약) trades under KRX code 225430 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Materials sector, Chemicals.
How large is KM Pharmaceutical?
Its market capitalisation was US$3.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were KM Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, KM Pharmaceutical reported revenue of US$12.1M, an operating loss of US$2.2M and a net loss of US$3M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was up 10.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 8
- Trading suspension period changedOct 2
- Other management matter (voluntary)Oct 2
- Report on large shareholdings (5% rule) (standard)Sep 16
- Report on securities held by executives/major shareholdersSep 16
- Report on securities held by executives/major shareholdersSep 16
- Other management matter (voluntary)Sep 15
- Trading suspension period changedSep 15
- Other market noticeSep 15
- Trading suspensionSep 14
- Other market notice (delisting risk notice: market cap below threshold)Sep 7
- Other market notice (delisting risk notice: market cap below threshold)Aug 31
- Treasury share acquisition: results report
KM Pharmaceutical Co., Ltd. completed a treasury share buyback from August 10 to August 26, 2026, acquiring 171,897 common shares for US$217K, below the 207,612 shares planned in the July 27, 2026 material event report due to share-price movements during the period.
Treasury Shares · Aug 28 - Material event report (treasury share acquisition)
KM Pharmaceutical disclosed a plan to buy back its own shares worth US$205K, about 6.6% of its market value.
Treasury Shares · Jul 27 - Securities issuance results (voluntary) (third-party placement)
Kmpharmaceutical Co., Ltd. reported that its July 14, 2026 third-party placement rights offering was fully paid in on July 24, 2026, issuing 908,265 common shares for US$678K, with the new shares expected to list on August 7, 2026 under a one-year lock-up.
Capital raise · Jul 24 - Material event report (rights offering)
KM Pharmaceutical disclosed a private placement (third-party allotment) to raise US$672K, about 22.1% of its market value.
Capital raise · Jul 14 - Trading suspension (share consolidation/split registration)M&A · Apr 9